Flow Cytometry Assay Validation as a Biomarker Versus in a Drug Development Setting

Home > Science Hub > Flow Cytometry Assay Validation as a Biomarker Versus in a Drug Development Setting
Back to the list

June 9, 2018

Audrey Gagnon, Dominic Gagnon, Jean-Francois Poulin, Bader Yassine-Diab, Martin Lelaidier, Virginia Litwin

Flow Cytometry Assay Validation as a Biomarker Versus in a Drug Development Setting, ICCS Annual Meeting / Annual Clinical Cytometry Meeting 2018

Flow-Cytometry-Assay-Validation-as-a-Biomarker-Versus-in-a-Drug-Development-Setting

Download poster

You might also be interested by

CellTalk Blog

ELISpot vs. ICS: Optimizing Immune Monitoring in Clinical Trials with the Right Functional Assay

November 19, 2024

Immune Monitoring

More info

CellTalk Blog

Measure Target Engagement With Receptor Occupancy Assays by Flow Cytometry

September 17, 2024

Immune Monitoring

More info

Brochures & Infographics

High Performance Technologies for Cytokine Measurement

July 29, 2024

Immune Monitoring

More info

Brochures & Infographics

Cell Therapy

December 15, 2023

Histopathology

More info